MLTX

MoonLake Immunotherapeutics

38.37 USD
-0.06 (-0.16%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

MoonLake Immunotherapeutics stock is down -6.07% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 June’s closed higher than May. In the last 4 Unusual Options Trades, there were 3 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
03 May 17:42 16 Aug, 2024 50.00 CALL 100 12
06 May 19:27 17 Jan, 2025 45.00 PUT 61 9
16 May 19:42 19 Dec, 2025 65.00 CALL 48 1
18 Jun 14:43 19 Dec, 2025 65.00 CALL 71 53

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, or ankylosing spondylitis.

  • HC Wainwright & Co.
    Tue Jun 11, 06:34
    buy
    confirm
  • Needham
    Mon Jun 10, 13:46
    buy
    confirm